君實生物(688180.SH):2024年淨虧損12.8億元
格隆匯2月27日丨君實生物(688180.SH)公佈2024年度業績快報,營業總收入194,831.73萬元,同比增長29.67%,歸屬於母公司所有者的淨利潤-128,227.92萬元。報吿期內,公司營業收入增長,主要系商業化藥品的銷售收入與上年同期相比增長。截至報吿期末,公司已擁有特瑞普利單抗注射液(商品名:拓益®)、阿達木單抗注射液(商品名:君邁康®)、氫溴酸氘瑞米德韋片(商品名:民得維®)和昂戈瑞西單抗注射液(商品名:君適達®)四款商業化藥品。得益於公司商業化團隊銷售效率提升,特瑞普利單抗獲批適應症及納入國家醫保目錄適應症的增加,報吿期內公司核心產品特瑞普利單抗於國內市場銷售額同比大幅增長超過 60%。
公司亦持續拓展全球商業化網絡,截至本公吿披露日,特瑞普利單抗已在美國、歐盟、印度、英國、約旦、澳大利亞等國家和地區獲得批准上市,同時在新加坡的上市許可申請已受理。公司及各合作伙伴將積極推動特瑞普利單抗在合作區域的上市申報及商業化進程,並積極探索更多適應症在部分地區上市的可能性。隨着已獲批產品和適應症納入國家醫保目錄後可及性的提高,未來更多產品和適應症的陸續獲批上市,以及持續不斷的全球市場商業化拓展,公司的商業化競爭力將獲得持續提升。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.